Prevalence and treatment of Alopecia areata in Taif area, KSA (original) (raw)
Related papers
A Study Of Alopecia Areata And Its Associated Diseases At A Tertiary Care Hospital
Introduction: Alopecia areata is an autoimmune disorder characterized by patchy non scarring hair loss associated with many systemic diseases. There is paucity of clinical data among Asian population. Aim and Objective: To find out the demographic and clinical profile of alopecia areata and its association with various systemic and dermatological diseases. Material and Methods: The present descriptive study was conducted among selected 100 patients of alopecia areata who attended Skin and venereal disease OPD, S.V.B.P. hospital, L.L.R.M. Medical College, Meerut, from January 2016 to December 2016. A detail information regarding demographic profile, family history, history of any systemic disease was obtained on a pre tested and predesigned questionnaire. Detail examination and thyroid profile was done of all the study subjects. The collected data was compiled in MS Excel and analyzed on Epi info software version 3.7.2. Results: Out of 100 patients, 92 patients completed the study out of which 61 % were male. Most of the study subjects were in the age group of 21-30 yrs. Patchy hair loss was found to be present in 87% and its association with duration of illness was found statistically significant. Higher association was found in nail changes (13%) followed by vitiligo (9%) and thyroid disorder (7%). Conclusion: the present study concludes association of alopecia areata with systemic and dermatological diseases. Early diagnosis and treatment of alopecia areata can reduce the burden of associated diseases.
Advances in the management of alopecia areata
The Journal of dermatology, 2012
Spontaneous remission occurs in up to 80% of patients with limited patchy alopecia areata (AA) within 1 year. Therefore, not all patients of AA simplex/multiplex need extensive treatments, and "wait and see" is one of the choices for some patients. However, once the hair loss show progressive course, it is really difficult to manage well and may be recalcitrant to any treatment in some cases. Hair loss symptom is not life-threatening but severely decreases quality of life. There have been two widely known guidelines for AA from the British Association of Dermatologists and the National Alopecia Areata Foundation (USA). These guidelines have been substantial and provide clues for dermatologists but needed to be updated. Recently, the Japanese Dermatological Association also published a guideline for the management of AA. This guideline suggests treatments followed by recommendations and evidence levels. Several new treatments are added such as corticosteroid pulse therapy a...
Alopecia: introduction and overview of herbal treatment
Journal of chemical and pharmaceutical research, 2016
Alopecia areata is a prevalent autoimmune skin disease resulting in the loss of hair on the scalp and elsewhere on the body. It usually starts with one or more small, round, smooth patches on the scalp and can progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis). The scalp is the most commonly affected area, but the beard or any hair-bearing site can be affected alone or together with the scalp. Alopecia areata occurs in males and females of all ages, but onset often occurs in childhood. Over people 147 million worldwide have, had or will develop alopecia areata at some point in their lives. According to Ayurveda, pitta dosha is the primary cause of hair loss. Pitta dosha could be reversed through diet and lifestyle modifications. Ayurvedic medicine for hair loss contains herbs that can arrest hair fall and improve hair growth.
Efficacy of Trichloroacetic Acid in Patients with Alopecia Areata: A Clinico-Histopathological Study
International Journal of Medical Arts
Article information Background: Alopecia areata is an autoimmune disorder caused by a breakdown in the follicular immune privilege system, resulting in non-scarring hair loss. Many therapeutic options have been tested with variable results. Aim of the work: To assess the efficacy of trichloroacetic acid [TCA] 35% in patients of alopecia areata. Patients and Methods: This prospective cross-sectional study included 40 patients recruited from department of dermatology and venereology, Al-Hussein hospital. Every patient was treated by 3 sessions of TCA 35% with one-month intervals. The assessment was done by clinical, trichoscopy, and histopathological examination. Results: The study included 40 patients, 22 males [55%] and18 females [45%]. The mean age of studied patients was 25.6 ± 8.6 years with a minimum age of 16 years and a maximum age of 50 years. The duration of the disease ranged between 2 months and 10 years with a mean duration of 2.7 ± 2.5 years. Thirty patients [75%] showed improvement at the end of TCA sessions. Conclusion: Based on our findings, topical application of TCA 35% is a safe and effective treatment option for patients with alopecia areata. Moreover, it can be used in wide areas of the scalp and cases of alopecia totalis.
Indian Journal of Dermatology, Venereology, and Leprology, 2013
Alopecia areata (AA) is a common form of non-scarring hair loss of scalp and/or body. Genetic predisposition, autoimmunity, and environmental factors play a major role in the etiopathogenesis of AA. Patchy AA is the most common form. Atopy and autoimmune thyroiditis are most common associated conditions. Peribulbar and intrabulbar lymphocytic infl ammatory infi ltrate resembling "swarm of bees" is characteristic on histopathology. Treatment is mainly focused to contain the disease activity. Corticosteroids are the preferred treatments in form of topical, intralesional, or systemic therapy. Camoufl age in the form of wigs may be an alternative option in refractory cases.
Management of alopecia areata: an update
2012
Alopecia areata is a common, non-scarring, autoimmune disorder affecting any hair-bearing area. It is often psychologically devastating. This disorder occurs in both the sexes, in all age groups, and is characterized by the sudden appearance of circumscribed areas of hair loss on the scalp or other parts of the body. Various therapeutic approaches are presently available for managing alopecia areata including corticosteroids, contact sensitizers and immunosuppressants, but none have been shown to alter the course of the disease on a consistent basis.
Clinical guidelines of ukrainian hair research society. diagnosis and treatment of alopecia areata
Aktualʹnì problemi sučasnoï medicini, 2023
Alopecia areata is an immune-mediated disease resulting from the interaction of genetic factors and exogenous triggers, leading to the activation of the Janus Kinases-Signal Transducer and Activator of Transcription signaling pathway, the formation of non-specific autoimmune inflammation and disruption of immune tolerance of hair follicles. Alopecia areata has an unpredictable course with a non-scarring type of hair loss, it can affect the hair part of the head and/or hair in other areas, it can be manifested by damage to the nail plates. The psychotraumatic impact of this disease can be compared to the consequences of life-threatening or disabling diseases. For this reason, the degree of negative impact of alopecia areata on the quality of life may not correlate with the objective condition of patients, which is often not taken into account in the diagnosis and treatment of the disease. Despite the variety of treatment options available, achieving effective and safe disease control is not always straightforward. Treating patients with alopecia areata and comorbid conditions can be particularly challenging and may require close collaboration between specialists from various fields. For these and other reasons, there is significant dissatisfaction among patients regarding alopecia areata and its treatment. The systematic organization, unification, and adaptation of modern knowledge about alopecia areata have led to the creation of two algorithms: a diagnostic algorithm and a therapeutic algorithm. These algorithms provide a differentiated approach to patient management, with age, disease severity, clinical form, disease activity stage, comorbid pathology, prognostic factors, and patient quality of life taken into account. Agents with immunosuppressive action belong to the main group of drugs in the treatment of alopecia areata, according to the antigenic concept of the pathogenesis of the disease. Ongoing work is being done to update treatment protocols to include JAK inhibitors and other preparations, taking into based on new developments and the expanding pharmaceutical market.
The Efficacy of Azelaic Acid 20% Cream in the Treatment of Scalp Alopecia Areata
Iraqi Journal of Pharmacy
Introduction: Alopecia areata is a common, inflammatory, non-scarring type of hair loss that affects persons of both sexes and all age groups, with prevalence in the general population of approximately 0.1-0.2%. It is characterized by variable clinical presentations, ranging from single or multiple well-circumscribed patches of hair loss to extensive involvement with complete absence of body and scalp hair. Alopecia areata is an autoimmune disease of the hair follicle. Its pathogenesis is associated with loss of follicular immune privilege and T-cell mediated inflammatory response, leading to interruption of the hair growth cycle. The diagnosis of alopecia areata is usually based on clinical manifestations in addition to using severity of alopecia tool score. Currently, there is no treatment for alopecia areata approved by the US Food and Drugs Administration. However, several treatment modalities for alopecia areata have been introduced with variable outcomes. Although topical and systemic immunomodulators are the mainstay options, there is still a lack of high-quality randomized controlled trials supporting these treatment modalities. Topical Corticosteroids are considered the first-line therapy for patchtype alopecia areata. Azelaic acid is a dicarboxylic acid, derived from the fungus Pityrosporum ovale and is regarded as an effective topical therapy for patchy alopecia areata. Aim of study: The present study aims to measure the efficacy of topical azelaic acid cream 20% in the treatment of alopecia areata. Patients and Methods: The all 30 patients were collected from Erbil Dermatology Teaching Center. They were divided into two groups: group A includes fifteen patients on topical clobetasol propionate 0.05% cream; group B includes fifteen patients on topical azelaic acid 20% cream. Both treatment groups were followed up for period of around twelve weeks with monthly check up visits. Both drugs were applied topically once daily at night. Results: the comparison between the baseline and 12 weeks visits for each study group concerning severity of alopecia tool score shows that the mean of the score for both groups at 12 weeks visit is lower than that of baseline visit in a statistically significant way (group A, p=0.007, group B, p=0.036). Conclusions: This study showed that topical azelaic acid cream 20% has an acceptable efficacy in comparison to topical clobetasol ointment 0.05% in the treatment of localized alopecia areata of scalp and can be considered as a therapeutic option for this condition.